COPD Foundation announces new Bronchiectasis and NTM Care Center Network with support of Founding Sponsor Insmed

MIAMI, (February 26, 2024) - Bronchiectasis and NTM 360, a division of the COPD Foundation, has announced the launch of the Bronchiectasis and NTM Care Center Network (CCN), a groundbreaking initiative that will facilitate access to specialized care and support for hundreds of thousands of individuals with bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.

This innovative network will be implemented at 150 medical centers in diverse geographical locations nationwide over the next three years with support from Founding Sponsor Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The aim for the centers is to provide accurate, prompt diagnosis and outstanding standardized medical care, resources, and education.

"Our goals to improve care and quality of life, advance research towards a cure, and build widespread awareness can only be attained through bold vision and support from companies like Insmed," said Jean Wright, M.D., MBA, CEO of the COPD Foundation. "As the prevalence of these diseases and the economic burden grow, early detection and education efforts are more critical than ever. This collaboration, which also includes NTM Info & Research and a steering committee of world-renowned experts and patient representation, will transform the landscape of care for individuals with bronchiectasis and NTM lung disease, providing them with the care and resources they need to thrive."

Goals of the CCN include:

  1. Accelerating the time to diagnosis and delivering specialized, comprehensive, high-quality care.
  2. Educating health care teams about bronchiectasis and NTM lung disease and the care required to achieve and maintain the best possible outcomes.
  3. Supporting research and clinical trials and the development of real-world evidence.
  4. Delivering patient-centered education to improve long-term disease management.
  5. Increasing disease awareness as well as patient education and engagement.

"Having a meaningful impact on the patient community is what drives us at Insmed," said Will Lewis, Chair and Chief Executive Officer of Insmed. "The Bronchiectasis & NTM Care Center Network brings together the COPD Foundation, NTM Info & Research, and a steering committee of the top experts in the world with the goal of transforming care delivery for patients. We could not be prouder to serve as the Founding Sponsor and look forward to the many ways in which the CCN will benefit patients and their families for years to come."

In addition to the CCN, Bronchiectasis and NTM 360 is developing a patient-reported registry of individuals with bronchiectasis and NTM lung disease that will provide a greater wealth of data on patient experience and journey, and will impact the direction of education and research.

For more information, visit Bronchiectasis and NTM Care Center Network or

About Bronchiectasis and NTM Lung Disease
Bronchiectasis is a chronic lung disease characterized by enlarged airways that are thickened and/or scarred. These permanently widened airways lead to a buildup of mucus and impaired clearance of bacteria from the lungs. Between 340,000 and 522,000 adults are receiving treatment in the U.S.

Nontuberculous mycobacterial (NTM) lung disease is a chronic respiratory condition caused by certain types of mycobacteria commonly found in the environment, such as in soil and water. NTM lung disease predominantly affects individuals with compromised immune systems or pre-existing lung conditions, such as bronchiectasis and chronic obstructive pulmonary disease (COPD). NTM lung disease affects tens of thousands of individuals in the U.S. with rates of infection on the rise.

About the COPD Foundation
The COPD Foundation is a nonprofit organization whose mission is to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease. The Foundation does this through scientific research, education, advocacy, and awareness to prevent disease, slow progression, and find a cure. For more information, visit, or follow us on Twitter and LinkedIn.

Crystal Rothhaar
(786) 749-7104 x468